Fibroblast growth factor receptor 2
Synonyms: CD332, CEK3, “Crouzon syndrome”, ECT1, K-SAM, “Pfeiffer syndrome”, TK14, TK25, BEK, CFD, KGFR
The fibroblast growth factor is a receptor tyrosine kinase signaling pathway that fundamentally regulates embryogenesis, angiogenesis, tissue homeostasis, and wound repair1. Alterations in FGFR signaling are associated with a broad range of congenital craniofacial developmental disorders, and somatic mutations of FGFR also have a role in oncologic evolution. FGFR2 is one of the 4 highly conserved transmembrane tyrosine kinase receptors. The mechanisms of dysregulation of FGFR2 causing cancer include activating mutations, gene amplification, chromosomal translocations, altered splicing and germline single nucleotide polymorphisms2.
FGFR2 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb 28;8(9):16052.
2. Tsimafeyeu I, Ludes-Meyers J, Stepanova E, Daeyaert F, Khochenkov D, Joose JB, Solomko E, Van Akene K, Peretolchina N, Yin W, Ryabaya O. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. European Journal of Cancer. 2016 Jul 1;61:20-8.